On December 31, 2012, the US Food and Drug Administration (FDA) announced its approval of a new drug to treat multidrug-resistant tuberculosis (MDR-TB). The agency granted bedaquiline (Sirturo) “fast-track” approval, assessing its efficacy by a surrogate measure rather than an actual clinical outcome. The criterion was the capacity of the drug, compared with placebo, to convert a patient's sputum culture from positive to negative for Mycobacterium tuberculosis when added to a standard MDR-TB regimen.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 18
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.